Is MK-677 liver toxic? MK-677 (a synthetic ghrelin mimetic) has not proved liver toxic in controlled trials, but a published case links it to drug-induced liver injury: trials in older adults found it generally well tolerated, whereas that case describes raised liver enzymes (blood markers of liver-cell injury) in an otherwise healthy man after two months of MK-677 alone.
Those enzyme values returned to within normal limits after exposure ended. For the kidneys, a randomised trial found no serious adverse effects attributable to MK-677 in patients on haemodialysis, and kidney-area pain has been described only outside the published trials, mostly in combination with other compounds.
What is MK 677 in pharmacological terms? It is an orally active agonist of the ghrelin receptor (the cell-surface receptor for the hormone ghrelin), and it entered clinical research as one, the trials cited here being built on that property; growth hormone itself (the pituitary hormone that governs growth and metabolism) must be given subcutaneously as a medicine and then loses its pulsatile pattern, which MK-677 leaves intact. In the trial in older adults daily MK-677 raised growth hormone and insulin-like growth factor 1 (IGF-1, the growth factor that relays much of growth hormone’s action) into the young-adult range over 12 months without serious adverse effects, and investigators then extended the approach to patients with kidney failure (a group not previously studied with the compound) as the safety step required before larger trials.
Below, we compare the liver evidence and then the kidney evidence, setting beside one another the trials and an animal study, descriptions outside the trials and two case reports (each a published account of one patient). Throughout, we keep MK-677 alone apart from MK-677 combined with selective androgen receptor modulators (SARMs), compounds that act on the androgen receptor with tissue selectivity, and we leave the heart, glucose metabolism and fluid retention to the wider picture of MK-677 side effects.
Liver and kidney safety in the placebo-controlled trials
Across the research on MK-677, the two longest placebo-controlled trials gave MK-677 at 25 mg daily and found it generally well tolerated: the first followed 65 healthy adults aged 60 to 81 for two years and recorded no serious adverse effects, and the second gave the same daily amount of ibutamorenum to 292 postmenopausal women aged 64 to 85 for 12 to 18 months, with adverse events leading to withdrawal relatively infrequent. Neither published trial summary names a liver or kidney finding among the effects recorded.
Daily administration of MK-677 significantly increased growth hormone and insulin-like growth factor I levels to those of healthy young adults without serious adverse effects.
The recorded effects lay elsewhere. In the older adults the most frequent were increased appetite that subsided within a few months, transient mild lower-leg oedema (a swelling from fluid held in the tissues) and myalgia (a pain arising in skeletal muscle tissue); fasting glucose rose by 0.3 mmol/L, insulin sensitivity (the degree to which tissues respond to insulin) declined, and cortisol rose by 47 nmol/L, whereas the trial in women noted side effects mediated by growth hormone. None of these is a liver or kidney finding; each belongs among the wider ibutamoren side effects.
Both trials enrolled older adults and older women, populations that differ from the young, otherwise healthy men of the published case reports and of the descriptions outside the trials, so what they found about tolerance at older ages cannot simply be carried over to younger men.
Is MK-677 kidney toxic?
MK-677 produced no serious adverse effects attributable to the compound in the one trial of patients with kidney failure: a three-month randomised, blinded trial in 26 patients on haemodialysis, 22 of whom completed the full three months, which as a crossover trial gave each participant the compound and a placebo in turn. Its investigators framed it as a first step towards assessing efficacy and safety ahead of larger trials in protein-energy wasting (the loss of body protein and energy reserves in end-stage kidney disease); under MK-0677 IGF-1 rose 65% more than under placebo, and adverse effects were minimal.
Such a trial measures tolerance only over a short span and only after kidney failure, so its three months in patients already on dialysis say little about kidney tissue that still filters normally, and a second source of such data never materialised: a phase 2 trial of MK-0677 on lean body mass was planned in chronic kidney disease stage 4 and 5 (the severe and end stages of declining renal function), but its ClinicalTrials.gov record shows that the trial was withdrawn.
Liver injury in a healthy man after MK-677 alone
A 2025 case report describes an otherwise healthy man in his early 30s who developed transaminitis (a rise in blood levels of the aminotransferase enzymes) after two months of exposure to MK-677. The two aminotransferases are alanine aminotransferase (ALT), held mainly in liver cells, and aspartate aminotransferase (AST), found in liver and skeletal muscle alike, and after exposure ended the man’s liver function tests (a blood panel of liver enzymes and related markers) eventually returned to within normal limits.
Unlike the published case of MK-677 with a SARM, this case reports an effect of ibutamoren on the liver after exposure to a single compound, and its authors note that few published accounts link MK-677 to hepatotoxicity (an injury of liver tissue caused by a chemical substance). Since the record covers a single patient, it shows that drug-induced liver injury followed exposure to MK-677 in one man but cannot establish how often such injury occurs.
Liver enzymes in a measured case of MK-677 with a SARM
A published case report describes a 25-year-old man exposed daily for five weeks to MK-677 15 mg with LGD-4033 10 mg (a synthetic compound of the SARM class) and records AST and ALT rising above the values measured before exposure; blood samples were taken before, during and after the five weeks, so each change could be set against the man’s own baseline, and on that comparison ALT rose more than twice as far as AST.
[Figure 1. Blood marker changes in one combined case. Per cent change from each marker’s pre-exposure value in one 25-year-old man exposed daily to MK-677 15 mg with LGD-4033 10 mg for five weeks. ALT rose 205%, over twice AST’s rise; the product was never analysed, so MK-677’s share is unknown.]
Beyond the liver enzymes the same samples showed the lipid profile shifting unfavourably: total cholesterol and triglycerides rose, the low-density lipoprotein (LDL) fraction carrying cholesterol to tissues rose, and the high-density lipoprotein (HDL) fraction returning it to the liver fell; testosterone dropped too, the free form further than the total.
The changes in liver enzymes cannot be attributed to MK-677, because LGD-4033 was present throughout the same five weeks, the record concerns a single patient and the product was never analysed, so the case shows what one of the MK 677 combinations did in one man, not what MK-677 does to liver tissue on its own.
These data demonstrate that LGD-4033 and MK-677 increase several body composition parameters, whilst negatively impacting bone and several serum biomarkers.
Is MK-677 liver toxic, or is it just the RAD-140 taken with it?
MK-677 is described, outside the trial record, as a compound whose liver enzyme rises appear mostly alongside RAD-140, by far its most frequent partner in such descriptions; RAD-140 (testolone) is another orally active compound of the SARM class, and we supply it for laboratory research. Raised liver enzymes are widely reported after exposure to that pairing, yet which of the two compounds raised them is just as widely left open, and the same doubt extends to combinations that add LGD-4033.
Outside the published trials, RAD-140 liver toxicity is described as greater than that of MK-677, which is called mildly hepatotoxic or not at all; hepatotoxicity from YK-11 (a steroidal compound often grouped with SARMs) appears in one account of a combination with RAD-140 and MK-677; none of these descriptions separates the effect of MK-677 from that of the compounds combined with it, so the share of the secretagogue in the enzyme rises remains unresolved.
Can MK-677 stacked with RAD-140 cause serious liver injury?
MK-677 combined with RAD-140 is linked to severe unwanted effects in descriptions outside the trials, but those descriptions do not show serious liver injury: the pairing is widely linked to a broad burden of harm and often said to produce worse unwanted effects than anabolic-androgenic steroids. The accounts name these:
Raised liver enzymes, to which the pairing is widely linked
Insomnia, among the effects named most often
Lethargy, likewise among the most often named
Suppression of testosterone, named as often
Disturbed blood glucose, named as often
Digestive problems severe enough that exposure ended early, in a few accounts after a three-compound combination of RAD-140 and MK-677 with ostarine (MK-2866), another compound of the SARM class
In those accounts RAD-140 is never separated from MK-677, so the share of each compound in such effects stays unknown, and none of them ties the symptoms to a diagnosis confirmed by liver function tests, such as acute hepatitis (an inflammation of liver tissue that develops over days to weeks).
Does MK-677 cause kidney pain?
MK-677 has also been described as a source of kidney-area pain, often when combined with RAD-140, LGD-4033 or ostarine and sometimes with no partner compound named, the pain a pressure or ache in the lower back or beside one kidney, starting within days of exposure to MK-677 with LGD-4033 or ostarine and lying on the right side in one account, though these accounts leave open whether such pain arises in kidney tissue at all.
In descriptions beyond the trials, a single account of RAD-140 with MK-677 describes days of nausea and vomiting that led to hospital assessment, where blood tests showed a raised creatinine (a waste product of skeletal muscle metabolism cleared by the kidneys) together with a lower estimated glomerular filtration rate (eGFR, the calculated filtering capacity of the kidneys) and a high potassium, which the account names as the cause of the illness, treated with fluids given intravenously and a potassium-lowering solution given orally; since RAD-140 was involved throughout, the account cannot show what MK-677 does to kidney tissue.
Is lower back or side pain on MK-677 a kidney problem?
Accounts outside the published studies describe lower back pain during exposure to MK-677 as spreading round towards the abdomen near the waist, a pattern that leaves its source between the kidneys and the back uncertain: the pain is first taken for exertional tightness in the skeletal muscle of the lumbar region and in one account worsened sharply after exertion that loaded that muscle tissue, while a single account places such pain with RAD-140 on the kidneys and lethargy and brain fog with MK-677, so none of these descriptions settles whether the pain arises in kidney tissue or in the skeletal muscle of the lower back.
How high an ALT rise on MK-677 is too high?
An ALT rise on MK-677 has no generally agreed threshold for being too high, so such a rise is commonly read by the general rules for drug-induced liver injury: an ALT result is read against the testing laboratory’s reference range (the span of values within which most healthy adults fall), and readings slightly above that range are widely understood to be common and non-specific, often put down to alcohol, recent illness, other compounds or strenuous resistance training, since skeletal muscle also releases ALT.
ALT readings above a laboratory’s reference range have also been described as a recurring source of doubt in MK677 bloodwork, values close to the top of the range sometimes open to the same doubt, and one account sets ALT and AST within the reference range beside a raised creatinine, a divergence between the liver values and the kidney value.
In those accounts, read by the general rules for drug-induced liver injury, these signs give an ALT rise more weight, or less:
A rise is generally held to carry more weight when it sits well above the reference range.
It carries more weight when it keeps climbing on repeat testing.
It carries more weight when it comes with a raised bilirubin or other signs of liver dysfunction.
A rise that falls back once exposure ends is commonly described as pointing to a drug effect rather than to lasting injury.
Does TUDCA protect the liver on MK-677?
Tauroursodeoxycholic acid (TUDCA), which is a water-soluble bile salt derived from ursodeoxycholic acid, is generally held to be a plausible but unproven hepatoprotective agent, not one expected to protect liver tissue reliably during exposure to MK-677: any protective action is thought to come from easing endoplasmic reticulum stress and lowering the load of more toxic bile acids, but that evidence rests mostly on laboratory and animal models of cholestatic liver injury, fatty liver disease and liver fibrosis, and in humans evidence for protection against drug-induced liver injury is widely seen as limited and inconclusive, concerning mostly ursodeoxycholic acid, the parent compound.
Clinical case descriptions also record drug-induced liver injury during exposure to TUDCA itself, though the lack of proven protection is generally held to matter less than it might, because MK-677 is not regarded as a significant cause of drug-induced liver injury.
Accounts outside the published studies describe TUDCA as protecting liver tissue during exposure to MK-677 or LGD-4033 and say the same of N-acetylcysteine (NAC, a precursor of the antioxidant glutathione) and of milk thistle (a silymarin-rich plant extract); a few accounts weigh the three against one another, one calling TUDCA far stronger than NAC and milk thistle together, while another has liver enzymes staying raised despite all three combined, so these accounts point in different directions and settle nothing about the protection of liver tissue.
Does MK-677 cause frequent urination?
MK-677 is not generally held to cause frequent urination, and the symptom is not generally read as a sign that the compound acts on kidney tissue; the research literature more commonly describes the opposite tendency, fluid retention and mild peripheral oedema, a form of MK677 water retention widely understood to follow the growth hormone-driven retention of sodium and water, which matches the transient lower-leg oedema of the trial in older adults.
The usual qualification to that reading concerns blood glucose rather than the kidneys. MK 677 is commonly described as raising fasting glucose and lowering insulin sensitivity, the changes towards MK677 insulin resistance that the same trial recorded, and sugar high enough to pass into the urine is generally held to increase urine output, so when thirst accompanies frequent urination the two symptoms are generally seen as a reason to test kidney function together with glucose and glycated haemoglobin (a marker of the average over recent months); in that reading the symptom points first to sugar metabolism, not to a direct effect of the compound on kidney tissue.
How the trial amounts and timescales compare with the liver cases
In the two long trials the MK677 dose given was 25 mg daily, whereas the liver changes in the two case reports followed far shorter exposures, to MK677 alone in one and to MK-677 15 mg with LGD-4033 in the other, and in length the dialysis trial lay between the long trials and the case reports.
The liver changes in the case reports thus followed shorter exposures than those of the trials, and in the combined case a lower amount of MK-677, so the amount given and MK-677 exposure length alone cannot explain those changes, and the second compound in the combined case and the unknown contents of the products remain possible explanations; for the single-compound case the published summary states no dose, so the amount behind that enzyme rise is unknown.
[Figure 2. Exposure lengths in the trials and liver cases. Length of exposure to MK-677 in two placebo-controlled trials in older adults, a crossover trial in patients on haemodialysis and two single-patient case reports. The liver changes followed far shorter exposures than the trials, so length alone cannot explain them.]
What happened to the liver after exposure stopped
Liver enzyme values recovered in both case reports once exposure stopped, the liver function tests returning to normal limits in the single-compound case and the readings to baseline in the combined one, where AST, ALT and every other measured variable returned to what was measured before exposure apart from total and limb fat mass, bone area, total cholesterol and the LDL fraction. Neither record states the time course of that recovery as a figure, so neither shows how quickly the enzyme values normalised.
Do raised liver enzymes settle once MK-677 is stopped?
Raised liver enzyme values after MK-677 are generally held to settle once exposure ends, (the pattern usual for drug-induced liver injury of this kind), though the return to normal limits is commonly described as slow rather than immediate and the evidence specific to MK-677 is very limited. Such a rise is generally held not to have settled when, after exposure has ended, any of these signs appears, and all but the first are features of liver dysfunction widely understood to call for clinical assessment rather than time alone:
Readings that keep climbing or stay high on repeat testing
A rising bilirubin
Dark urine
Itching
Jaundice, a yellowing of the skin and eyes
Why the contents of the case-report products are unknown
The product in the measured combined case was never analysed, so its true contents and strength are unknown, and in the single-compound case MK-677 was contained in a performance-enhancing supplement whose analysis the published summary does not record, so a change in liver enzymes after exposure to an unanalysed product cannot be tied with certainty to its declared compound.
The MK-677 for sale at Maxmusclelabs.com is supplied for laboratory research with batch and purity data (the measured identity and content of each production lot), set out in a certificate of analysis (a laboratory report on the identity and purity of a batch), and the same report accompanies each compound in our range of SARMs for sale.
Could a mislabelled MK-677 product explain raised liver enzymes?
A mislabelled MK-677 product is generally held to be a plausible explanation for raised liver enzymes, since analyses of products sold as MK-677 or as SARMs are commonly described as finding the stated compound missing, present at a different strength or accompanied by undeclared substances, among them orally active anabolic-androgenic steroids well known to cause drug-induced liver injury; a product that has never been analysed is widely treated as having unknown contents, because the label is the only evidence of what it holds and such products sit outside pharmaceutical quality control, and that uncertainty is commonly described as the main obstacle to tying a liver enzyme rise to ibutamoren itself, which only chemical analysis of the material can confirm or exclude.
What a rat study showed about the ghrelin receptor in the kidney
A 2020 rat study traced the role in kidney function of GHS-R1a (the ghrelin receptor that MK-677 acts on), which is expressed mainly in the brain but also in the kidneys. Acting through that receptor, ibutamoreno changed measures of osmolarity (the concentration of dissolved particles in a fluid) in spontaneously hypertensive rats (a strain that develops high blood pressure), whereas blocking the receptor in normal Wistar rats lowered urinary sodium and potassium and also creatinine clearance (the kidneys’ rate of clearing creatinine); that fall was not seen in the hypertensive strain, which also carried lower levels of receptor protein in both the kidneys and the brain.
These data describe how the receptor shapes kidney function and blood flow in an animal model, and they are not a finding of kidney injury in humans.
What the liver and kidney evidence on MK-677 cannot show
Whether MK-677 is liver toxic in young, healthy adults is beyond the liver and kidney evidence, which rests on populations and study designs that cannot be extended to them: both long trials enrolled older participants, healthy adults in one and postmenopausal women in the other, the kidney data come from a short trial in patients already on dialysis, and on the liver side the case report after MK-677 alone describes a single man while the measured combined case concerns one man exposed to two compounds from a product that was never analysed. No rate of liver or kidney injury can be drawn for young, healthy adults, and the sources stand one by one in the table.
The liver and kidney evidence by source
Source
Who was studied
Design
Liver or kidney finding
Older adults trial, 2008
65 healthy adults aged 60 to 81
2-year randomised placebo-controlled trial
No liver or kidney finding named; no serious adverse effects
Postmenopausal women trial, 2001
292 women aged 64 to 85
18-month randomised placebo-controlled trial
No liver or kidney finding named; withdrawals for adverse events relatively infrequent
Haemodialysis trial, 2018
26 patients on haemodialysis enrolled, 22 completed
3-month randomised blinded crossover trial
No serious adverse effects attributable to MK-677
Kidney disease trial record, 2009
Chronic kidney disease stage 4 and 5
Phase 2 trial, withdrawn
None: the trial was withdrawn
Rat study, 2020
Wistar rats and spontaneously hypertensive rats
Animal study
Ghrelin receptor blocking lowered creatinine clearance in Wistar rats; no human kidney injury
Case report, 2025
One man in his early 30s
Case report
Transaminitis after MK-677 alone, resolved after stopping
Case report, 2022
One 25-year-old man
Case report with measurements before, during and after
AST +95.8%, ALT +205.0% with LGD-4033 present
No published study among this article’s sources has measured any of the effects described only outside the published trials: pain in the kidney area and the lower back, liver enzyme rises after MK-677 combined with RAD-140, and any protective effect of TUDCA, NAC or milk thistle on liver tissue.
The one regulatory listing on ibutamoren, the FDA’s compounding entry, concerns MK677 heart problems and adds nothing to the evidence on the liver and the kidneys.
Important information. This article summarises published research and case reports, and notes where effects are described outside the published trials. It is not medical advice, and Max Muscle Labs does not give dosing guidance or any information implying human use. Many of the compounds discussed here are not approved for human use by the MHRA, the FDA or any other regulator, and many are prohibited in sport by WADA. Products sold by Max Muscle Labs are supplied strictly for laboratory and analytical research use and are not for human or veterinary consumption.
Check what you remember
4 questions on this article; the right answer is marked.
What did the 2025 case report on MK-677 alone describe in an otherwise healthy man?
Raised liver enzymes that persisted for a year after exposure ended
Raised liver enzymes that returned to normal after exposure ended ✓
Acute kidney injury with a raised creatinine and potassium
Raised liver enzymes that appeared only with a SARM present
The man's liver function tests returned to within normal limits after exposure ended, though a single case cannot show how often such injury occurs.
In the case report of a man exposed to MK-677 together with LGD-4033, why can the rises in liver enzymes not be pinned on MK-677?
The enzyme rises stayed within the laboratory's reference range
No baseline blood sample existed to compare the rises against
LGD-4033 was present throughout and the product was never analysed ✓
Resistance training in the same weeks could account for the ALT rise
LGD-4033 was present for the same five weeks and the product was never analysed, so the AST and ALT rises cannot be tied to MK-677.
What did the randomised trial of MK-677 in patients on haemodialysis find?
A fall in kidney filtering capacity that led investigators to stop the trial
Raised liver enzymes in most patients receiving MK-677
Fluid retention severe enough to call for extra dialysis sessions
No serious adverse effects attributable to MK-677 over three months ✓
Adverse effects were minimal in the three-month crossover trial, though kidneys already in failure say little about kidneys that still filter normally.
What safety concern underlies the FDA's listing of ibutamoren mesylate for compounding?
Potential congestive heart failure ✓
Potential drug-induced liver injury
Potential decline in kidney function
Potential rise in fasting glucose
The FDA listed ibutamoren mesylate for potential congestive heart failure, a concern about the heart that adds nothing on liver or kidney tissue.
Nina Meyer is a specialist in internal medicine in the Department of Endocrinology and Metabolism at Charité Universitätsmedizin Berlin. Nina specialises in metabolic endocrinology and the growth hormone and IGF-1 axis.
RAD 140 lethargy, like aggression, anxiety and insomnia, is unproven: the only human trial, in 22 women, listed none among its frequent adverse events.
Raised liver function tests were the commonest RAD 140 side effects in the only full human trial; case reports add liver injury and heart inflammation.
Is MK-677 liver toxic? The liver and kidney evidence
By Ailsa Gemmell · Reviewed by Nina Meyer
Published · Updated · 20 min read
Is MK-677 liver toxic?
Is MK-677 liver toxic? MK-677 (a synthetic ghrelin mimetic) has not proved liver toxic in controlled trials, but a published case links it to drug-induced liver injury: trials in older adults found it generally well tolerated, whereas that case describes raised liver enzymes (blood markers of liver-cell injury) in an otherwise healthy man after two months of MK-677 alone.
Those enzyme values returned to within normal limits after exposure ended. For the kidneys, a randomised trial found no serious adverse effects attributable to MK-677 in patients on haemodialysis, and kidney-area pain has been described only outside the published trials, mostly in combination with other compounds.
What is MK 677 in pharmacological terms? It is an orally active agonist of the ghrelin receptor (the cell-surface receptor for the hormone ghrelin), and it entered clinical research as one, the trials cited here being built on that property; growth hormone itself (the pituitary hormone that governs growth and metabolism) must be given subcutaneously as a medicine and then loses its pulsatile pattern, which MK-677 leaves intact. In the trial in older adults daily MK-677 raised growth hormone and insulin-like growth factor 1 (IGF-1, the growth factor that relays much of growth hormone’s action) into the young-adult range over 12 months without serious adverse effects, and investigators then extended the approach to patients with kidney failure (a group not previously studied with the compound) as the safety step required before larger trials.
Below, we compare the liver evidence and then the kidney evidence, setting beside one another the trials and an animal study, descriptions outside the trials and two case reports (each a published account of one patient). Throughout, we keep MK-677 alone apart from MK-677 combined with selective androgen receptor modulators (SARMs), compounds that act on the androgen receptor with tissue selectivity, and we leave the heart, glucose metabolism and fluid retention to the wider picture of MK-677 side effects.
Liver and kidney safety in the placebo-controlled trials
Across the research on MK-677, the two longest placebo-controlled trials gave MK-677 at 25 mg daily and found it generally well tolerated: the first followed 65 healthy adults aged 60 to 81 for two years and recorded no serious adverse effects, and the second gave the same daily amount of ibutamorenum to 292 postmenopausal women aged 64 to 85 for 12 to 18 months, with adverse events leading to withdrawal relatively infrequent. Neither published trial summary names a liver or kidney finding among the effects recorded.
The recorded effects lay elsewhere. In the older adults the most frequent were increased appetite that subsided within a few months, transient mild lower-leg oedema (a swelling from fluid held in the tissues) and myalgia (a pain arising in skeletal muscle tissue); fasting glucose rose by 0.3 mmol/L, insulin sensitivity (the degree to which tissues respond to insulin) declined, and cortisol rose by 47 nmol/L, whereas the trial in women noted side effects mediated by growth hormone. None of these is a liver or kidney finding; each belongs among the wider ibutamoren side effects.
Both trials enrolled older adults and older women, populations that differ from the young, otherwise healthy men of the published case reports and of the descriptions outside the trials, so what they found about tolerance at older ages cannot simply be carried over to younger men.
Is MK-677 kidney toxic?
MK-677 produced no serious adverse effects attributable to the compound in the one trial of patients with kidney failure: a three-month randomised, blinded trial in 26 patients on haemodialysis, 22 of whom completed the full three months, which as a crossover trial gave each participant the compound and a placebo in turn. Its investigators framed it as a first step towards assessing efficacy and safety ahead of larger trials in protein-energy wasting (the loss of body protein and energy reserves in end-stage kidney disease); under MK-0677 IGF-1 rose 65% more than under placebo, and adverse effects were minimal.
Such a trial measures tolerance only over a short span and only after kidney failure, so its three months in patients already on dialysis say little about kidney tissue that still filters normally, and a second source of such data never materialised: a phase 2 trial of MK-0677 on lean body mass was planned in chronic kidney disease stage 4 and 5 (the severe and end stages of declining renal function), but its ClinicalTrials.gov record shows that the trial was withdrawn.
Liver injury in a healthy man after MK-677 alone
A 2025 case report describes an otherwise healthy man in his early 30s who developed transaminitis (a rise in blood levels of the aminotransferase enzymes) after two months of exposure to MK-677. The two aminotransferases are alanine aminotransferase (ALT), held mainly in liver cells, and aspartate aminotransferase (AST), found in liver and skeletal muscle alike, and after exposure ended the man’s liver function tests (a blood panel of liver enzymes and related markers) eventually returned to within normal limits.
Unlike the published case of MK-677 with a SARM, this case reports an effect of ibutamoren on the liver after exposure to a single compound, and its authors note that few published accounts link MK-677 to hepatotoxicity (an injury of liver tissue caused by a chemical substance). Since the record covers a single patient, it shows that drug-induced liver injury followed exposure to MK-677 in one man but cannot establish how often such injury occurs.
Liver enzymes in a measured case of MK-677 with a SARM
A published case report describes a 25-year-old man exposed daily for five weeks to MK-677 15 mg with LGD-4033 10 mg (a synthetic compound of the SARM class) and records AST and ALT rising above the values measured before exposure; blood samples were taken before, during and after the five weeks, so each change could be set against the man’s own baseline, and on that comparison ALT rose more than twice as far as AST.
Beyond the liver enzymes the same samples showed the lipid profile shifting unfavourably: total cholesterol and triglycerides rose, the low-density lipoprotein (LDL) fraction carrying cholesterol to tissues rose, and the high-density lipoprotein (HDL) fraction returning it to the liver fell; testosterone dropped too, the free form further than the total.
The changes in liver enzymes cannot be attributed to MK-677, because LGD-4033 was present throughout the same five weeks, the record concerns a single patient and the product was never analysed, so the case shows what one of the MK 677 combinations did in one man, not what MK-677 does to liver tissue on its own.
Is MK-677 liver toxic, or is it just the RAD-140 taken with it?
MK-677 is described, outside the trial record, as a compound whose liver enzyme rises appear mostly alongside RAD-140, by far its most frequent partner in such descriptions; RAD-140 (testolone) is another orally active compound of the SARM class, and we supply it for laboratory research. Raised liver enzymes are widely reported after exposure to that pairing, yet which of the two compounds raised them is just as widely left open, and the same doubt extends to combinations that add LGD-4033.
Outside the published trials, RAD-140 liver toxicity is described as greater than that of MK-677, which is called mildly hepatotoxic or not at all; hepatotoxicity from YK-11 (a steroidal compound often grouped with SARMs) appears in one account of a combination with RAD-140 and MK-677; none of these descriptions separates the effect of MK-677 from that of the compounds combined with it, so the share of the secretagogue in the enzyme rises remains unresolved.
Can MK-677 stacked with RAD-140 cause serious liver injury?
MK-677 combined with RAD-140 is linked to severe unwanted effects in descriptions outside the trials, but those descriptions do not show serious liver injury: the pairing is widely linked to a broad burden of harm and often said to produce worse unwanted effects than anabolic-androgenic steroids. The accounts name these:
In those accounts RAD-140 is never separated from MK-677, so the share of each compound in such effects stays unknown, and none of them ties the symptoms to a diagnosis confirmed by liver function tests, such as acute hepatitis (an inflammation of liver tissue that develops over days to weeks).
Does MK-677 cause kidney pain?
MK-677 has also been described as a source of kidney-area pain, often when combined with RAD-140, LGD-4033 or ostarine and sometimes with no partner compound named, the pain a pressure or ache in the lower back or beside one kidney, starting within days of exposure to MK-677 with LGD-4033 or ostarine and lying on the right side in one account, though these accounts leave open whether such pain arises in kidney tissue at all.
In descriptions beyond the trials, a single account of RAD-140 with MK-677 describes days of nausea and vomiting that led to hospital assessment, where blood tests showed a raised creatinine (a waste product of skeletal muscle metabolism cleared by the kidneys) together with a lower estimated glomerular filtration rate (eGFR, the calculated filtering capacity of the kidneys) and a high potassium, which the account names as the cause of the illness, treated with fluids given intravenously and a potassium-lowering solution given orally; since RAD-140 was involved throughout, the account cannot show what MK-677 does to kidney tissue.
Is lower back or side pain on MK-677 a kidney problem?
Accounts outside the published studies describe lower back pain during exposure to MK-677 as spreading round towards the abdomen near the waist, a pattern that leaves its source between the kidneys and the back uncertain: the pain is first taken for exertional tightness in the skeletal muscle of the lumbar region and in one account worsened sharply after exertion that loaded that muscle tissue, while a single account places such pain with RAD-140 on the kidneys and lethargy and brain fog with MK-677, so none of these descriptions settles whether the pain arises in kidney tissue or in the skeletal muscle of the lower back.
How high an ALT rise on MK-677 is too high?
An ALT rise on MK-677 has no generally agreed threshold for being too high, so such a rise is commonly read by the general rules for drug-induced liver injury: an ALT result is read against the testing laboratory’s reference range (the span of values within which most healthy adults fall), and readings slightly above that range are widely understood to be common and non-specific, often put down to alcohol, recent illness, other compounds or strenuous resistance training, since skeletal muscle also releases ALT.
ALT readings above a laboratory’s reference range have also been described as a recurring source of doubt in MK677 bloodwork, values close to the top of the range sometimes open to the same doubt, and one account sets ALT and AST within the reference range beside a raised creatinine, a divergence between the liver values and the kidney value.
In those accounts, read by the general rules for drug-induced liver injury, these signs give an ALT rise more weight, or less:
Does TUDCA protect the liver on MK-677?
Tauroursodeoxycholic acid (TUDCA), which is a water-soluble bile salt derived from ursodeoxycholic acid, is generally held to be a plausible but unproven hepatoprotective agent, not one expected to protect liver tissue reliably during exposure to MK-677: any protective action is thought to come from easing endoplasmic reticulum stress and lowering the load of more toxic bile acids, but that evidence rests mostly on laboratory and animal models of cholestatic liver injury, fatty liver disease and liver fibrosis, and in humans evidence for protection against drug-induced liver injury is widely seen as limited and inconclusive, concerning mostly ursodeoxycholic acid, the parent compound.
Clinical case descriptions also record drug-induced liver injury during exposure to TUDCA itself, though the lack of proven protection is generally held to matter less than it might, because MK-677 is not regarded as a significant cause of drug-induced liver injury.
Accounts outside the published studies describe TUDCA as protecting liver tissue during exposure to MK-677 or LGD-4033 and say the same of N-acetylcysteine (NAC, a precursor of the antioxidant glutathione) and of milk thistle (a silymarin-rich plant extract); a few accounts weigh the three against one another, one calling TUDCA far stronger than NAC and milk thistle together, while another has liver enzymes staying raised despite all three combined, so these accounts point in different directions and settle nothing about the protection of liver tissue.
Does MK-677 cause frequent urination?
MK-677 is not generally held to cause frequent urination, and the symptom is not generally read as a sign that the compound acts on kidney tissue; the research literature more commonly describes the opposite tendency, fluid retention and mild peripheral oedema, a form of MK677 water retention widely understood to follow the growth hormone-driven retention of sodium and water, which matches the transient lower-leg oedema of the trial in older adults.
The usual qualification to that reading concerns blood glucose rather than the kidneys. MK 677 is commonly described as raising fasting glucose and lowering insulin sensitivity, the changes towards MK677 insulin resistance that the same trial recorded, and sugar high enough to pass into the urine is generally held to increase urine output, so when thirst accompanies frequent urination the two symptoms are generally seen as a reason to test kidney function together with glucose and glycated haemoglobin (a marker of the average over recent months); in that reading the symptom points first to sugar metabolism, not to a direct effect of the compound on kidney tissue.
How the trial amounts and timescales compare with the liver cases
In the two long trials the MK677 dose given was 25 mg daily, whereas the liver changes in the two case reports followed far shorter exposures, to MK677 alone in one and to MK-677 15 mg with LGD-4033 in the other, and in length the dialysis trial lay between the long trials and the case reports.
The liver changes in the case reports thus followed shorter exposures than those of the trials, and in the combined case a lower amount of MK-677, so the amount given and MK-677 exposure length alone cannot explain those changes, and the second compound in the combined case and the unknown contents of the products remain possible explanations; for the single-compound case the published summary states no dose, so the amount behind that enzyme rise is unknown.
What happened to the liver after exposure stopped
Liver enzyme values recovered in both case reports once exposure stopped, the liver function tests returning to normal limits in the single-compound case and the readings to baseline in the combined one, where AST, ALT and every other measured variable returned to what was measured before exposure apart from total and limb fat mass, bone area, total cholesterol and the LDL fraction. Neither record states the time course of that recovery as a figure, so neither shows how quickly the enzyme values normalised.
Do raised liver enzymes settle once MK-677 is stopped?
Raised liver enzyme values after MK-677 are generally held to settle once exposure ends, (the pattern usual for drug-induced liver injury of this kind), though the return to normal limits is commonly described as slow rather than immediate and the evidence specific to MK-677 is very limited. Such a rise is generally held not to have settled when, after exposure has ended, any of these signs appears, and all but the first are features of liver dysfunction widely understood to call for clinical assessment rather than time alone:
Why the contents of the case-report products are unknown
The product in the measured combined case was never analysed, so its true contents and strength are unknown, and in the single-compound case MK-677 was contained in a performance-enhancing supplement whose analysis the published summary does not record, so a change in liver enzymes after exposure to an unanalysed product cannot be tied with certainty to its declared compound.
The MK-677 for sale at Maxmusclelabs.com is supplied for laboratory research with batch and purity data (the measured identity and content of each production lot), set out in a certificate of analysis (a laboratory report on the identity and purity of a batch), and the same report accompanies each compound in our range of SARMs for sale.
Could a mislabelled MK-677 product explain raised liver enzymes?
A mislabelled MK-677 product is generally held to be a plausible explanation for raised liver enzymes, since analyses of products sold as MK-677 or as SARMs are commonly described as finding the stated compound missing, present at a different strength or accompanied by undeclared substances, among them orally active anabolic-androgenic steroids well known to cause drug-induced liver injury; a product that has never been analysed is widely treated as having unknown contents, because the label is the only evidence of what it holds and such products sit outside pharmaceutical quality control, and that uncertainty is commonly described as the main obstacle to tying a liver enzyme rise to ibutamoren itself, which only chemical analysis of the material can confirm or exclude.
What a rat study showed about the ghrelin receptor in the kidney
A 2020 rat study traced the role in kidney function of GHS-R1a (the ghrelin receptor that MK-677 acts on), which is expressed mainly in the brain but also in the kidneys. Acting through that receptor, ibutamoreno changed measures of osmolarity (the concentration of dissolved particles in a fluid) in spontaneously hypertensive rats (a strain that develops high blood pressure), whereas blocking the receptor in normal Wistar rats lowered urinary sodium and potassium and also creatinine clearance (the kidneys’ rate of clearing creatinine); that fall was not seen in the hypertensive strain, which also carried lower levels of receptor protein in both the kidneys and the brain.
These data describe how the receptor shapes kidney function and blood flow in an animal model, and they are not a finding of kidney injury in humans.
What the liver and kidney evidence on MK-677 cannot show
Whether MK-677 is liver toxic in young, healthy adults is beyond the liver and kidney evidence, which rests on populations and study designs that cannot be extended to them: both long trials enrolled older participants, healthy adults in one and postmenopausal women in the other, the kidney data come from a short trial in patients already on dialysis, and on the liver side the case report after MK-677 alone describes a single man while the measured combined case concerns one man exposed to two compounds from a product that was never analysed. No rate of liver or kidney injury can be drawn for young, healthy adults, and the sources stand one by one in the table.
The liver and kidney evidence by source
No published study among this article’s sources has measured any of the effects described only outside the published trials: pain in the kidney area and the lower back, liver enzyme rises after MK-677 combined with RAD-140, and any protective effect of TUDCA, NAC or milk thistle on liver tissue.
The one regulatory listing on ibutamoren, the FDA’s compounding entry, concerns MK677 heart problems and adds nothing to the evidence on the liver and the kidneys.
Check what you remember
4 questions on this article; the right answer is marked.
The man's liver function tests returned to within normal limits after exposure ended, though a single case cannot show how often such injury occurs.
LGD-4033 was present for the same five weeks and the product was never analysed, so the AST and ALT rises cannot be tied to MK-677.
Adverse effects were minimal in the three-month crossover trial, though kidneys already in failure say little about kidneys that still filter normally.
The FDA listed ibutamoren mesylate for potential congestive heart failure, a concern about the heart that adds nothing on liver or kidney tissue.
Ailsa Gemmell · NHS Greater Glasgow and Clyde
Specialty Registrar in Gastroenterology
Ailsa Gemmell is a specialty registrar in gastroenterology at NHS Greater Glasgow and Clyde. Ailsa specialises in hepatology and liver safety.
Nina Meyer · Charité Berlin · Last reviewed
Specialist in Internal Medicine
Nina Meyer is a specialist in internal medicine in the Department of Endocrinology and Metabolism at Charité Universitätsmedizin Berlin. Nina specialises in metabolic endocrinology and the growth hormone and IGF-1 axis.
Related Posts
RAD 140 teenager: what a case report and animal data show
RAD 140 teenager evidence records harm: myopericarditis in a 16-year-old boy after his first dose, and raised frailty and mortality risk in mice.
RAD 140 lethargy: mood, sleep and what the evidence shows
RAD 140 lethargy, like aggression, anxiety and insomnia, is unproven: the only human trial, in 22 women, listed none among its frequent adverse events.
RAD 140 side effects: what the trials and case reports show
Raised liver function tests were the commonest RAD 140 side effects in the only full human trial; case reports add liver injury and heart inflammation.
How bad is RAD-140 for the heart? What the evidence shows
How bad is RAD-140 for the heart remains unmeasured in published studies, while case reports describe myocarditis and heart failure after exposure.